Dehydroretronecine-induced skin tumors in mice.
Female Swiss mice susceptible to skin tumors received 6 sc injections and/or topical applications of dehydroretronecine, a metabolite of the pyrrolizidine alkaloid monocrotaline, and were observed for 15 months for tumor development. Of 92 animals examined, 63 had tumors at the site of application or injection; 47 of these had skin tumors, mainly basal cell and squamous cell carcinomas. These data indicate that dehydroretronecine is a proximate carcinogen capable of causing a high incidence of skin tumours in mice at the site of sc injection or topical application.
D000287:Administration, Topical; D000818:Animals; D002280:Basal Cell Carcinoma / Q000139:chemically induced* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D007279:Injections, Subcutaneous; D051379:Mice; D016686:Monocrotaline / Q000031:analogs & derivatives; D009374:Neoplasms, Experimental / Q000139:chemically induced; D011763:Pyrrolizidine Alkaloids / Q000008:administration & dosage / Q000633:toxicity*; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology
D011763:Pyrrolizidine Alkaloids; D016686:Monocrotaline; C007241:dehydroretronecine